A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses

• Published in: Human vaccines & immunotherapeutics 2022-11, Vol.18 (6), p.2100189-2100189
• Main Authors: Nistor, Gabriel I., Dillman, Robert O., Robles, Rockelle M., Langford, James L., Poole, Aleksandra J., Sofro, Muchlis A. U., Nency, Yetty M., Jonny, Jonny, Yana, Martina L., Karyana, Mahammad, Lestari, Endang S., Triwardhani, Ria, Mujahidah, Mujahidah, Sari, Retty K., Soetojo, Nur A., Wibisono, Djoko, Tjen, Daniel, Ikrar, Taruna, Sarkissian, Gregory, Winarta, Haryono, Putranto, Terawan A., Keirstead, Hans S.
• Format: Article
• Language: English
• Subjects: Antibodies, Viral; Coronavirus; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunity, Cellular; Personal vaccine; phase 1; phase 2; Point-of-Care Systems; SARS-CoV-2; Spike Glycoprotein, Coronavirus
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2022.2100189

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish the feasibility of personal dendritic cell vaccines to the SARS-CoV-2 spike protein, establish the safety of a single subcutaneous vaccine injection, and determine the antigen-specific immune response following vaccination. In Phase 1, 31 subjects were assigned to one of nine formulations of autologous dendritic cells and lymphocytes (DCL) incubated with 0.10, 0.33, or 1.0 µg of recombinant SARS-CoV-2 spike protein, and admixed with saline or 250 or 500 µg of granulocyte-macrophage colony-stimulating factor (GM-CSF) prior to injection, then assessed for safety and humoral response. In Phase 2, 145 subjects were randomized to one of three formulations defined by incubation with the same three quantities of spike protein without GM-CSF, then assessed for safety and cellular response. Vaccines were successfully manufactured for every subject at point-of-care. Approximately 46.4% of subjects had a grade 1 adverse event (AE); 6.5% had a grade 2 AE. Among 169 evaluable subjects, there were no acute allergic, grade 3 or 4, or serious AE. In Phase 1, anti-receptor binding domain antibodies were increased in 70% of subjects on day-28. In Phase 2, in the 127 subjects who did not have high levels of gamma interferon-producing cells at baseline, 94.4% had increased by day 14 and 96.8% by day 28. Point-of-care personal vaccine manufacturing was feasible. Further development of such subject-specific vaccines is warranted.